# CRONOS GROUP INC. (CRON) · Edgar & Edgarette company card

> Cronos Group (CRON) grew revenue 19.5% in FY2025 to $193 million, operating margin -9.0% against a 0.7% median for medicinal chemicals & botanical products, equity 91.4% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1656472 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/CRON) · [JSON](https://www.pops4.com/boards/company/CRON.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $193M |
| Revenue growth, 1 year | 19.5% |
| Revenue growth per year | 24.8% |
| Operating margin | -9.0% (prior year -47.3%) |
| Net margin | -4.9% |
| Operating cash flow | $26M |
| Capital spending | $26M |
| Free cash flow | $149,000 |
| Cash | $792M |
| Long-term debt | — |
| Total assets | $1.2B |
| Total equity | $1.1B |
| Equity ÷ assets | 91.4% |
| Return on equity | -0.9% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: 27.23 (safe zone)
- Piotroski F: 7 of 9 (solid)
- Beneish M: -1.88 (below the −1.78 line)
- Health Harbor boat: Sound ship · one warning sign · operating loss: a margin of -9.0% in FY2025
- Cash Compass: Cash cow later · growing fast, and already turning revenue into cash

## Edgarette's reading

Exposure: revenue $193.4M (FY2025). Experience: revenue up 19.5% on the year, up 24.8% a year over 4 years; operating margin -9.0%, up from -47.3%. Soundness: equity 91.4% of assets, return on equity -0.9%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $192.5M and $269.9M next year (method v4.1: its own 4-year record of growth weighed at 50% against $100M–1B filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $176.7M to $295.0M. A statistical range, not company guidance. Against peers (10 filers, $50M+ revenue, medicinal chemicals & botanical products): operating margin -9.0% against a 0.7% median; growth 19.5% against 1.7%.

Range logged 2026-09-24, receipt 676d60b526893f1d, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

No warning filings in the window.

## Recent filings

- 8-K · filed 2026-10-15 · 1.01 Entry into a Material Definitive Agreement; 2.01 Completion of Acquisition or Disposition of Assets; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1656472/000165647226000061/0001656472-26-000061-index.htm)
- 8-K · filed 2026-09-11 · 1.01 Entry into a Material Definitive Agreement; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1656472/000165647226000058/0001656472-26-000058-index.htm)
- 10-Q · filed 2026-08-06 · [filing](https://www.sec.gov/Archives/edgar/data/1656472/000165647226000051/0001656472-26-000051-index.htm)
- 8-K · filed 2026-08-06 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1656472/000165647226000050/0001656472-26-000050-index.htm)
- 8-K · filed 2026-06-22 · 5.07 Submission of Matters to a Vote of Security Holders · [filing](https://www.sec.gov/Archives/edgar/data/1656472/000165647226000039/0001656472-26-000039-index.htm)
- 10-Q · filed 2026-05-11 · [filing](https://www.sec.gov/Archives/edgar/data/1656472/000165647226000033/0001656472-26-000033-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001656472.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1656472

## Cite

POPS4, Edgar & Edgarette: CRONOS GROUP INC. (CRON) company card, from the company's own SEC filings, accessed 2026-11-04, https://www.pops4.com/boards/company/CRON. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.